Home › Colorectal Cancer › Massachusetts
Colorectal Cancer clinical trials in Massachusetts
62 studies for Colorectal Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Nov 6, 2026 · NCT06983743Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06324357Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Boston
- Clinical Study Site, Danvers
- Clinical Study Site, Newton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07228832A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07542704A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07578571Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Boston Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05673148A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06720987A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital - Dana Farber, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT03526835LYL273 for Patients With Relapsed or Refractory mCRC
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05319314A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Massachusetts General Hospital, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07284849A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Dana-Farber Cancer Institute /ID# 270624, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06820463A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06835569Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- Massachusetts General Brigham, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06026410Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05786924A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Massachusetts General Hospital /ID# 273608, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT07023289Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
- Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07222800FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Dana Farber/Partners Cancer Care Inc, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04429542A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07544589The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Recruiting
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06565052A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06445062Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07349537Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 to 50 · All sexes · Updated Sep 11, 2026 · NCT06202183Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT04899908A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07227168Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.